Menu
← Oncology Approval Tracker
FDA DECISION ·
Krazati
adagrasib · Mirati Therapeutics
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with locally advanced or metastatic NSCLC harboring KRAS G12C on an FDA-approved test after at least one previous systemic therapy.
LAMPGEN ANALYSIS
Why it matters
The approval adds a targeted treatment option for previously treated KRAS G12C-positive NSCLC.
What research teams should watch
Capture the precise KRAS variant and systemic treatment history. Coordinate medication interaction review and adherence follow-up.
PRIMARY RECORDS